This study is a randomized, double-blind, controlled phase III trial in regard to adjuvant toripalimab versus placebo combined with chemotherapy for EGFR/ALK mutation-negative stage II-IIIB (N2) (AJCC 8th TNM stage) NSCLC (48). The gene discussed is ALK; the disease is non-small cell lung carcinoma.